A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver
Sponsor: University of California, San Diego
Suspended
This study was terminated due to expired drug with possibility of re-starting in the future.
Listed as NCT00546455, this PHASE2 trial focuses on Insulin Resistance and Obesity and remains suspended. Sponsored by University of California, San Diego, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Suspended PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Suspended PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Suspended PHASE2
▶ Show 5 earlier versions
-
Mar 2021 — Dec 2021 [monthly]
Suspended PHASE2
Status: Unknown Status → Suspended
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .